Detalhe da pesquisa
1.
Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
Cancer Metastasis Rev
; 42(2): 481-505, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37022618
2.
Bridging the gaps: management of lichen planus subtypes in a joint dermatology-oral surgery clinic.
Clin Exp Dermatol
; 49(1): 18-25, 2023 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37768125
3.
Seborrheic keratosis.
J Dtsch Dermatol Ges
; 21(3): 265-277, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892019
4.
Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells.
Int J Mol Sci
; 22(6)2021 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33799879
5.
ß2 Integrins-Multi-Functional Leukocyte Receptors in Health and Disease.
Int J Mol Sci
; 21(4)2020 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32092981
6.
Seborrhoische Keratosen.
J Dtsch Dermatol Ges
; 21(3): 265-278, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36929560
7.
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study.
Cancers (Basel)
; 15(5)2023 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900217
8.
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.
J Immunother Cancer
; 11(9)2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37730278
9.
The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma-A Retrospective, Real-World Cohort Study.
Cancers (Basel)
; 14(9)2022 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35565212
10.
eHealth Literacy in German Skin Cancer Patients.
Int J Environ Res Public Health
; 19(14)2022 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35886215
11.
ß2 Integrins on Dendritic Cells Modulate Cytokine Signaling and Inflammation-Associated Gene Expression, and Are Required for Induction of Autoimmune Encephalomyelitis.
Cells
; 11(14)2022 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35883631
12.
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry.
Cancers (Basel)
; 14(22)2022 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36428636
13.
Protease- and cell type-specific activation of protease-activated receptor 2 in cutaneous inflammation.
J Thromb Haemost
; 20(12): 2823-2836, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36161697
14.
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment.
Cancers (Basel)
; 13(2)2021 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33430105
15.
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges.
Target Oncol
; 16(5): 537-552, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34554353
16.
Merkel Cell Carcinoma: From Pathobiology to Clinical Management.
Biology (Basel)
; 10(12)2021 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34943208
17.
Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study.
Cancers (Basel)
; 13(20)2021 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34680252
18.
New diagnostic and imaging technologies in dermatology.
J Cosmet Dermatol
; 20(12): 3782-3787, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34652880
19.
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.
Cancers (Basel)
; 13(10)2021 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34065877
20.
Tumor necrosis factorrelated apoptosisinducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against firstline chemotherapy.
Oncol Rep
; 43(4): 1331-1337, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32020226